Paolo Zanella was educated in the mathematical and physical sciences at the University of Bologna. He is now professeur honoraire (emeritus) of the University of Geneva, where he has been a professor of Computer Science at the Faculty of Sciences since 1983. He is a Fellow of the ACM (Association for Computing) since 1997. He has been the first Director of the European Bioinformatics Institute, Cambridge, UK, from 1993 to 1998.
He headed the Data Handling Division of CERN (Geneva) from 1976 to 1989 and then joined the General Direction as advisor to the DG for information technology and network strategy. He was the first CEO and Scientific Director of CRS4, an institute created in 1990 in Sardinia to develop internet/web technology, mathematical modelling and simulation to bridge the gap between industrial and academic research. He worked on strategic papers for the EU Commission to promote high-performance computers and networks. Over a period of 40 years he has worked with computers applying IT to a variety of domains, managed projects and large divisions of International Organisations at the forefront of European research in High-Energy Physics, Molecular Biology and the Information Sciences, achieving substantial technical and scientific results.
After retiring in 1998, he co-founded high-technology start-up companies, served on many advisory and executive boards, and he is now familiar with the problems and challenges of the private enterprise. He is a member of the IOD (Institute of Directors) in the UK. As a consultant, he has worked for several Governmental Research Organisations.

David J. Mazzo, Ph.D., joined Chugai Pharma USA, LLC in April 2003. Dr. Mazzo is a pharmaceutical executive and strategic leader with broad technical and managerial experience gained from working in a variety of multi-cultural and multi-lingual environments in the USA and Europe. He is recognized for his strong scientific and regulatory expertise, upon which he has amassed a track record of ~ 20 years of successful global product development, registration and launch.
Dr. Mazzo has spent his entire career within the pharmaceutical industry, rising quickly from the bench to occupy positions of increasing responsibility with Merck, Baxter, Rhône-Poulenc Rorer, Hoechst Marion Roussel and Schering-Plough. The technical diversity of his assignments has resulted in an expertise across all therapeutic areas as well as the whole of the drug development process from Discovery to Manufacturing.
Dr. Mazzo earned his Ph.D. in Analytical Chemistry at the University of Massachusetts (Amherst). He holds an M.S. in Chemistry from the same institution as well as dual degrees [B.S. in Chemistry and B.A. in Honors (Interdisciplinary Humanities)] from Villanova University. He additionally complemented his American education as a Research Fellow at the Ecole Polytechnique Fédérale de Lausanne in Switzerland.
Dr. Mazzo has published often and is frequently invited to present at international meetings on a wide variety of topics. He regularly contributes to the education of the next generation of scientists and leaders by teaching at the University of Massachusetts and Temple University, among others. He is an active member of several scientific and professional societies, including AAPS, ACS, DIA, and AOAC International. Dr. Mazzo is the editor of International Stability Testing, a reference text for regulators and the pharmaceutical industry, and has been a contributing editor of Analytical Profiles of Drug Substances and Excipients since 1989. He also has made contributions to the ICH guidelines for stability (Q1A/B/C), impurities in drug substances and drug products (Q3A/B), and the common technical registration dossier (M4) and has served as a member of the Orally Inhaled and Nasal Drug Products subcommittee of the FDA Advisory Committee for Pharmaceutical Science.

Dominique Gillot came to HP after many years of experience in high Performance computing within Digital and then Compaq before Compaq and HP merged.
After several years of management of the High energy physics Market in Europe, Dominique Gilllot started the High Performance Technical market for Digital and Compaq In Europe and drove it for 6 years, dealing with the Largest High Performance Technical Computing projects for Digital and Compaq in Europe.
For the last three years Dominique has focused on the emerging but booming Life Science Bioiformatics business In Europe and is presently managing this business For HP.
One of the key efforts driven by Dominique within HP is to work very closely with HPlabs in order to bring the very latest IT techniques available to increase the Productivity of IT R&D activities.
Dominique is also involved in several collaborations between HP and Bio researchers like the Vital-IT centre recently Opened near by Lausanne, focusing on Bioinformatics.

Neil Bell is the Managing Director of Paradigm Pharma, a knowledge-networked company focused on insourcing high value ‘drug development specialists’ into pharmaceutical and biotechnology companies. Paradigm Pharma has an international network of ‘specialists’ experienced in developing and facilitating executable strategies within the field of drug development.
Neil graduated in Genetics from the University of Liverpool in 1983 and moved to the University of St. Andrews to complete a higher degree in Biophysics. Following a period working with the UK Government, Neil moved into academic research and joined the bone marrow transplant research group at the Royal Free Hospital in London to undertake clinical research into leukaemia. In 1987 he joined the pharmaceutical industry and moved to Roussel where he specialised in the clinical-marketing interface and developed his knowledge of clinical research practice and operational marketing within a UK affiliate. Joining the Japanese pharmaceutical company Eisai, in 1989, Neil played a key role in building the European clinical development group and worked extensively with his US and Japanese collegues to build a world-wide development organisation. During this period Neil was involved with several global development programmes including Aricept for the treatment of Alzheimers and Pariet for the treatment of acid-related diseases. Working with Eisai, Neil developed his expertise in drug development from Phase I to Phase III and product launch. In 1997 Neil moved to Pfizer, Central Research where he was involved with several drug development projects in early and late phase. Whilst at Pfizer Neil was part of the assessment team responsible for recommending the in-licencing of the COPD drug Spiriva from Boehringer Ingelheim and was also involved in deploying a newly developed outsourcing process to facilitate CRO selection and management. It was at Pfizer that Neil developed his interest in Electronic Data Capture (EDC) and electronic patient diaries and worked with his project teams to deploy these technologies worldwide. Neil was then asked to join Ipsen in 1999 as International Director of Clinical Development and participated in several initiatives to strengthen Ipsen’s global presence including a milestone R&D portfolio review resulting in a therapeutic aligned R&D organization. Neil went on to establish Paradigm Pharma in early 2004 to capitalise on his experience within the pharma sector and develop alternative resourcing models for drug development organisations. Neil is a member of the Institute of Directors in the UK and acts as a consultant to several companies in UK and Europe with an interest in developing new technologies to enhance the facilitation of the drug development process.

James D. Utterback is an entrepreneurial executive with P&L experience building start-ups and public organizations in healthcare software, products and services on three continents. Utterback's extensive experience includes CEO of a successful start-up healthcare IT venture; founder of a healthcare consulting firm with capabilities in Tokyo, Japan and U.S.; national, regional and global P&L management; new product and service launches; acquisitions and alliances in Asia-Pacific, Europe & Africa; integration support of global $1 billion+ pharmaceutical merger ; and taking public a Fortune 1500 NYSE Company. As CEO and Board Member (2000-2002) at PHT Corporation, a global leader in providing e-clinical services to healthcare organizations, Utterback accelerated growth to commercial success through aggressive direct sales and alliance strategy, restructuring the organization and developing appropriately sized process and systems infrastructures. As corporate senior vice president and operating president (1994-99) at Covance (NYSE: CVD), one of the world's largest and most comprehensive biopharmaceutical development service companies with revenues over $800 million, Utterback built two thriving new organizations - Global Ventures and The Client Relations Group. At Rhone-Poulenc Rorer Pharmaceuticals (1984-94), Utterback served as CEO, Sub-Saharan Africa (1993-94), with full P&L management of the manufacturing plant, three divisions, 250 employees, and $23 million sales. Jim started his career with GE Medical Systems(1979-1984) After graduating cum laude with a B.A., Psychology/Economics, from Washington & Lee University in 1977, Utterback graduated summa cum laude with an M.S., Industrial Psychology, from Virginia Polytechnic Institute in 1979. He has completed executive courses at the University of Virginia, Darden School, and Harvard Business School. Utterback is a member of PhRma and DIA.

Charles Bellaiche is currently Global Services Principal for a major Global Pharmaceutical company at HP. Most recently Charles has been heading the Pharmaceutical/Life Sciences Industry Segment worldwide, after leading HP Corporate Account Sales and Industries in Western Europe, with a specific personal focus on the Manufacturing industry segment. Prior to this assignment, Charles had been for 6 years HP Global Client Business Manager for a leading Global Pharmaceutical company headquartered in Switzerland. His organization of sales and services professionals had the mission to provide superior customer satisfaction, to help clients achieve global operational excellence and gain a competitive advantage in their market, by matching HP's solutions with their identified needs.
Charles has been 24 years with HP and has had a number of sales and marketing management positions in various HP businesses, including medical devices, printers, HP 3000 systems, UNIX systems, technical workstations, where he also had a direct sales as well a channels experience.He started his career at HP in its Medical Products Group, with a specific focus on obstetrical and neonatal applications, as sales development engineer. He has a degree as "Ingénieur Civil Des Mines" from the "Ecole Nationale Supérieure des Mines de Paris (France)".